Oxford Global Conferences are proud to present our highly anticipated 3rd Annual Stem Cell Congress, taking place on the 3–4 November 2016 at the Radisson Blu Portman Hotel, London, UK. The conference programme consists of world-class keynote addresses, industry and academic led presentations, as well as ample networking opportunities, creating an interactive platform for high-level scientific and business discussions.
Over 250 delegates representing internationally renowned research & academic institutions, clinical research institutions, stem cell therapy companies as well as leading pharmaceutical and biotech companies.
Over 20 presentations and case studies focusing on the key issues in stem cell therapy development, commercialisation, and iPSC Bioprocessing including tissue engineering and organ regeneration.
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities.
Co-located with the established 5th Annual Cell Culture & Bioprocessing Congress and 2nd Annual Cell & Gene Therapy Congress
The global stem cell therapy market is an increasingly exciting field for academia and the pharmaceutical industry which is advancing rapidly. The market is expected to reach $330 million by 2020 and experts have stated that we are on the ‘edge of a major stem cell breakthrough’. Extraordinary progress has been made through successful clinical trial studies with the future of stem cell therapies said to be the ‘answer to various possibilities in the future of medical science’. The aim for researchers is to ultimately make stem cell therapies an effective, low-cost treatment widely available to treat a variety of diseases.
Day one of the congress will focus on Stem Cell & iPSC Bioprocessing. Representatives from leading academic stem cell organisations will provide exciting case studies discussing stem cell and regenerative medicine bioprocessing strategies, stem cell manufacturing, as well as advances in reprogramming & transdifferentiation techniques. Another key area for day one is the derivation, manipulation and characterisation of iPSCs and ensuring controlled growth and differentiation.
Day two of the congress will focus on stem cell therapy development: clinical trials & commercialisation. Delegates will have the opportunity to hear about cell based therapies for use in regenerative medicine, innovations in tissue engineering & organ regeneration, as well as stem cell metabolism in tissue development. Stem cell therapies to treat age related diseases in order to meet the needs of our ever increasing aging population will also be discussed.